(CNN) A clinical trial for an HIV vaccine has been\ndiscontinued since the vaccine was not found to prevent infections of human\nimmunodeficiency virus, the virus that causes AIDS.<\/p>\n\n\n\n
The National Institute of Allergy and Infectious Diseases or\nNIAID, which sponsored the trial, announced on Monday that the study taking\nplace in South Africa was halted after an independent data and safety\nmonitoring board found the vaccine to be ineffective in preventing HIV. NIAID\nnoted that the board did not express any concerns about safety.<\/p>\n\n\n\n
“An HIV vaccine is essential to end the global\npandemic, and we hoped this vaccine candidate would work. Regrettably, it does\nnot,” Dr. Anthony Fauci, director of the NIAID, said in a written\nstatement on Monday.<\/p>\n\n\n\n
“Research continues on other approaches to a safe and\neffective HIV vaccine, which I still believe can be achieved,” he said.<\/p>\n\n\n\n
Scientists cautiously optimistic about HIV vaccine candidate<\/p>\n\n\n\n
In a separate news release, the Global HIV Vaccine\nEnterprise announced “deep disappointment” that the vaccine study had\nbeen stopped. The enterprise is an alliance of funders and stakeholders formed\nto accelerate the search for an HIV vaccine.<\/p>\n\n\n\n
“Whilst this is a significant setback for the field, we\nneed to continue the quest for a preventive vaccine. The rates of HIV\ninfection, which continue unabated in this region, should spur greater urgency,\nglobal attention and investment to the quest,” Linda-Gail Bekker,\nimmediate past president of the International AIDS Society and chair of the\nEnterprise Advisory Group, said in that separate announcement.<\/p>\n\n\n\n
New HIV vaccine to be trialled in South Africa<\/p>\n\n\n\n
The vaccine trial, named HVTN 702 or Uhambo, began in 2016\nand enrolled 5,407 HIV-negative volunteers at 14 sites across South Africa,\naccording to NIAID. Those volunteers were sexually active men and women ages 18\nto 35 who were randomly assigned to receive either the vaccine or placebo\ninjections.<\/p>\n\n\n\n
An analysis of the study showed no significant difference in\nsubsequent HIV infections among the volunteers in the vaccine group versus\nplacebo group. According to NIAID, 129 HIV infections occurred among the\nvaccine recipients and 123 HIV infections occurred among the placebo\nrecipients. NIAID said that those study participants are being informed of the\ntrial stopping and researchers will continue to follow study participants over\ntime.<\/p>\n\n\n\n
This trial wasn’t the\nonly investigation into approaches to prevent HIV. The National Institutes of\nHealth has invested in two other late-stage, multinational HIV vaccine trails,\nboth testing a novel vaccine regimen, among other HIV prevention trials.<\/p>\n\n\n\n
Additionally, the use of a daily pill to prevent HIV\ninfection called PrEP rose almost 500% from 2014 to 2017 in the United States,\naccording to research published in July by the US Centers for Disease Control\nand Prevention.<\/p>\n\n\n\n
In December, US Health and Human Services Secretary Alex\nAzar announced the launch of a national program to provide free HIV-prevention\ndrugs to uninsured adults in the United States at risk of HIV.<\/p>\n","protected":false},"excerpt":{"rendered":"
(CNN) A clinical trial for an HIV vaccine has been discontinued since the vaccine was not found to prevent infections of human immunodeficiency virus, the virus that causes AIDS. The National Institute of Allergy and Infectious Diseases or NIAID, which…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1484","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/ril-va.org\/index.php?rest_route=\/wp\/v2\/posts\/1484","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ril-va.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ril-va.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ril-va.org\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ril-va.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1484"}],"version-history":[{"count":1,"href":"https:\/\/ril-va.org\/index.php?rest_route=\/wp\/v2\/posts\/1484\/revisions"}],"predecessor-version":[{"id":1485,"href":"https:\/\/ril-va.org\/index.php?rest_route=\/wp\/v2\/posts\/1484\/revisions\/1485"}],"wp:attachment":[{"href":"https:\/\/ril-va.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1484"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ril-va.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1484"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ril-va.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1484"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}